



# TEXAS MEDICAID

## Clinical Edit Prior Authorization tocilizumab (ACTEMRA)

STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING	
Date:	Prescriber First & Last Name:
Patient First & Last Name:	Prescriber NPI:
Patient Address:	Prescriber Address:
Patient ID:	Prescriber Phone:
Patient Date of Birth:	Prescriber Fax:
STEP 2: MEDICATION INFORMATION	
Medication Requested (Name):	Quantity Requested:
Dose Requested:	Dosing Instructions:
Patient's Primary Diagnosis: _____ ICD 10 Code: _____	
Please indicate ONE (1) of the following: <input type="checkbox"/> STAR / STAR KIDS client <b>(Go to Step 3 - PDL PA Criteria Applies)</b> <b>OR</b> <input type="checkbox"/> CHIP / PERINATE client <b>(Go to Step 4)</b>	
STEP 3: PDL PRIOR AUTHORIZATION CRITERIA FOR NON-PREFERRED PRODUCT	
1. Has the client failed a 30-day treatment trial with at least one (1) preferred agent in the last 180 days? <input type="checkbox"/> Yes (Go to Step 4 Question 1) <input type="checkbox"/> No (Go to #2)	
2. Is there a documented allergy or contraindication to preferred agents in this class? <input type="checkbox"/> Yes (Go to Step 4 Question 1) <input type="checkbox"/> No (Go to #3)	
3. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions? <input type="checkbox"/> Yes (Go to Step 4 Question 1) <input type="checkbox"/> No (Deny)	



**STEP 4: CLINICAL PRIOR AUTHORIZATION CRITERIA**

1. Is the client greater than or equal to ( $\geq$ ) 18 years of age?

Yes (Go to #2)

No (Go to #5)

2. Does the client have a diagnosis of Rheumatoid Arthritis (RA) in the last 730 days?

Yes (Go to #4)

No (Go to #3)

3. Does the client have a diagnosis of Giant Cell Arteritis (GCA) in the last 730 days?

Yes (Go to #7)

No (Go to #5)

4. Does the client have one (1) claim for a disease modifying anti-rheumatic drug (DMARD) in the last 180 days?

Examples of DMARDs include azathioprine (IMURAN), cyclosporine (GENGRAF, NEORAL, SANDIMMUNE), hydroxychloroquine (PLAQUENIL), leflunomide (ARAVA), methotrexate (OTREXUP, TREXALL, XATMEP), and sulfasalazine (AZULFIDINE).

Yes (Go to #7)

No - And the request is for continuing therapy (Go to #7)

No - And the request is for initial therapy (Deny)

5. Does the client have a diagnosis of Polyarticular Juvenile Idiopathic Arthritis (PJIA) or Systemic Juvenile Idiopathic Arthritis (SJIA) in the last 730 days?

Yes (Go to #6)

No (Deny)

6. Is the client greater than or equal to ( $\geq$ ) 2 years of age?

Yes (Go to #7)

No (Deny)

7. Does the client have a serious active infection (including Hepatitis B virus and/or tuberculosis) in the last 180 days?

Yes (Deny)

No (Approve – 365 days)

**STEP 5: SIGN AND FAX TO: NAVITUS PRIOR AUTHORIZATION AT: 855-668-8553**

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

If criteria not met, submit chart documentation with form citing complex medical circumstances. For questions, please call Navitus Customer Care at 1-877-908-6023.